Is there a threshold for the deleterious effect of smoking in Crohn's disease?
Reddy
Raghuram P
RP
Miles and Shirley Fiterman Center for Digestive Diseases, Division of Gastroenterology and Hepatology, Mayo Clinic, Minnesota, USA.
Tremaine
William J
WJ
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy / Q000453:epidemiology* / Q000473:pathology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D008297:Male; D009017:Morbidity; D012008:Recurrence; D012307:Risk Factors; D012720:Severity of Illness Index; D012737:Sex Factors; D012907:Smoking / Q000009:adverse effects* / Q000473:pathology; D016540:Smoking Cessation; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab